Exchange: NASDAQ·Updated 06:24 AM EST

CAPR News

News
all
press releases
US Stock Futures Rise As Democrats Make Midterm Gains — AMD, SMCI, PLTR, SPCX, DJT In Focus
Oil prices also edged higher as markets awaited Washington’s next move in the war in Iran.
Stocktwits
US Stock Futures Rise As Democrats Make Midterm Gains — AMD, SMCI, PLTR, SPCX, DJT In Focus
Oil prices also edged higher as markets awaited Washington’s next move in the war in Iran.
Stocktwits
More News
CAPR Stock Rises As Clinical Trial Investigators Write To FDA Urging Approval For Deramiocel
The FDA is slated to decide on approving Capricor’s drug for the treatment of Duchenne muscular dystrophy by November 22.
Stocktwits
FDA Decision Watch: Regeneron And Roche’s Autoimmune Drugs, Capricor’s DMD Therapy In Spotlight
November brings several closely watched FDA decisions, with Regeneron and its partner Alnylam’s therapy for generalized myasthenia gravis and Roche’s Gazyva for primary membranous nephropathy in the spotlight this week.
Stocktwits
CAPR Stock Rallies Into FDA Decision Month: Retail Spots Approval ‘Tea Leaves’ In Capricor’s Launch Team Hiring
Capricor is recruiting two commercial bosses, with both listings for the preparations for a potential Deramiocel launch.
Stocktwits
Commit To Buy Capricor Therapeutics At $3, Earn 69.5% Annualized Using Options
Investors considering a purchase of Capricor Therapeutics Inc (Symbol: CAPR) shares, but cautious about paying the going market price of $6.33/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in...
Nasdaq News: Markets
CAPR Stock on Track For Worst Month Since July AdCom Vote On Deramiocel As November FDA Decision Nears
The FDA is slated to decide on approving Capricor’s Deramiocel for the treatment of Duchenne muscular dystrophy by November 22.
Stocktwits
CAPR Stock Rises Nearly 5% As Capricor Presents Heart Data For Deramiocel Ahead Of November FDA Decision
Craig McDonald said on Wednesday that in patients in the HOPE-3 trial with weakened hearts, Deramiocel treatment produced “essentially complete stabilization” over a year.
Stocktwits
Capricor’s DMD Therapy Shows 76% Slower Upper-Limb Decline — This Analyst Expects A Complete Response Letter In November
Capricor’s Phase 3 HOPE-3 open-label extension data shows significant improvement in upper limb decline, but H.C. Wainwright said it did not remove the statistical uncertainty from the original trial.
Stocktwits
CAPR Stock Clocks Best Day In Over A Month As 24-Month Duchenne Data Airs At Medical Conference In Japan
The company is slated to orally present long-term trial results of deramiocel at the World Muscle Society congress in Hiroshima on October 3.
Stocktwits
Capricor Therapeutics Stock Surges: What's Going On?
Shares of Capricor Therapeutics Inc. (NASDAQ: CAPR) are trading higher Wednesday morning following the release of positive long-term clinical data for its lead cellular therapy. read more...
Benzinga

Advertisement|Remove ads.